Valproic Acid in Childhood Progressive Brain Tumors
|ClinicalTrials.gov Identifier: NCT01861990|
Recruitment Status : Withdrawn (Feasibility of the trial was proven to be absent.)
First Posted : May 24, 2013
Last Update Posted : May 22, 2015
|Condition or disease||Intervention/treatment||Phase|
|Pediatric Brain Tumor Glioma Anaplastic Astrocytoma Medulloblastoma Glioblastoma||Drug: Valproic Acid||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Valproic Acid for Children With Recurrent and Progressive Brain Tumors|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Experimental: Treatment arm
All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
Drug: Valproic Acid
All participants enrolled on valproic acid arm.
Other Name: Valproate, VPA, Depakote, Depakote ER, Depakene
- Completion of protocol [ Time Frame: 2 months ]Number of participants completing the protocol will be measured.
- Time to progression [ Time Frame: 2 months ]Participants will be evaluated for progression every 2 months while on the study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01861990
|United States, South Carolina|
|Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Principal Investigator:||Amy L Bredlau, MD||Medical University of South Carolina|